UCB SA's (EBR:UCB) dividend will be increasing to €0.91 on 3rd of May. This takes the annual payment to 0.8% of the current stock price, which unfortunately is below what the industry is paying.
View our latest analysis for UCB
UCB's Dividend Is Well Covered By Earnings
The dividend yield is a little bit low, but sustainability of the payments is also an important part of evaluating an income stock. However, UCB's earnings easily cover the dividend. This means that most of what the business earns is being used to help it grow.
Looking forward, earnings per share is forecast to fall by 25.8% over the next year. If the dividend continues along the path it has been on recently, we estimate the payout ratio could be 23%, which is comfortable for the company to continue in the future.
UCB Has A Solid Track Record
The company has an extended history of paying stable dividends. Since 2012, the dividend has gone from €1.00 to €1.30. This implies that the company grew its distributions at a yearly rate of about 2.7% over that duration. Although we can't deny that the dividend has been remarkably stable in the past, the growth has been pretty muted.
The Dividend Looks Likely To Grow
The company's investors will be pleased to have been receiving dividend income for some time. It's encouraging to see UCB has been growing its earnings per share at 14% a year over the past five years. UCB definitely has the potential to grow its dividend in the future with earnings on an uptrend and a low payout ratio.
We Really Like UCB's Dividend
Overall, we think this could be an attractive income stock, and it is only getting better by paying a higher dividend this year. The earnings easily cover the company's distributions, and the company is generating plenty of cash. We should point out that the earnings are expected to fall over the next 12 months, which won't be a problem if this doesn't become a trend, but could cause some turbulence in the next year. Taking this all into consideration, this looks like it could be a good dividend opportunity.
Market movements attest to how highly valued a consistent dividend policy is compared to one which is more unpredictable. Still, investors need to consider a host of other factors, apart from dividend payments, when analysing a company. Companies that are growing earnings tend to be the best dividend stocks over the long term. See what the 20 analysts we track are forecasting for UCB for free with public analyst estimates for the company. Looking for more high-yielding dividend ideas? Try our collection of strong dividend payers.
New: AI Stock Screener & Alerts
Our new AI Stock Screener scans the market every day to uncover opportunities.
• Dividend Powerhouses (3%+ Yield)
• Undervalued Small Caps with Insider Buying
• High growth Tech and AI Companies
Or build your own from over 50 metrics.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About ENXTBR:UCB
UCB
A biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide.
Reasonable growth potential with adequate balance sheet.
Similar Companies
Market Insights
Community Narratives
![Unike](https://media.simplywall.st/news/1706674307668-no-image.png)
![Investingwilly](https://media.simplywall.st/news/1706674307668-no-image.png)
![Jonataninho](https://media.simplywall.st/news/1706674307668-no-image.png)